Ofatumumab with ICE or DHAP Chemotherapy in B Cell Lymphoma (2011 ASH Conference)

VIDEO | 02:00

In patients with early relapse or refractory disease following first-line treatment, the efficacy of second-line rituximab combined with salvage chemotherapy is lower in patients previously treated with rituximab combined with chemotherapy compared to patients treated with chemotherapy alone. Ofatumumab (OFA), a fully human monoclonal antibody against CD20, uses an alternate binding site from that of rituximab, and demonstrates more potent complement-dependent cytotoxicity in vitro than does rituximab.

Medical oncologist Matthew Matasar discusses how the inclusion of OFA in second-line therapy could improve response rates for aggressive B-cell non-Hodgkin’s lymphoma relapsing after, or refractory to, rituximab-containing initial therapy.